Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. / Hawkey, Christopher J; Ell, Christian; Simon, Bernd; Albert, Joerg; Keuchel, Martin; Mcalindon, Mark; Fortun, Paul; Schumann, Stefan; Bolten, Wolfgang; Shonde, Anthony; Hugot, Jean-Louis; Yu, Vincent; Arulmani, Udayasankar; Krammer, Gerhard; Rebuli, Rosemary; Toth, Ervin.

I: Clinical Gastroenterology and Hepatology, Vol. 6, Nr. 5, 2008, s. 536-544.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Hawkey, CJ, Ell, C, Simon, B, Albert, J, Keuchel, M, Mcalindon, M, Fortun, P, Schumann, S, Bolten, W, Shonde, A, Hugot, J-L, Yu, V, Arulmani, U, Krammer, G, Rebuli, R & Toth, E 2008, 'Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole', Clinical Gastroenterology and Hepatology, vol. 6, nr. 5, s. 536-544. https://doi.org/10.1016/j.cgh.2007.12.023

APA

Hawkey, C. J., Ell, C., Simon, B., Albert, J., Keuchel, M., Mcalindon, M., ... Toth, E. (2008). Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clinical Gastroenterology and Hepatology, 6(5), 536-544. https://doi.org/10.1016/j.cgh.2007.12.023

CBE

Hawkey CJ, Ell C, Simon B, Albert J, Keuchel M, Mcalindon M, Fortun P, Schumann S, Bolten W, Shonde A, Hugot J-L, Yu V, Arulmani U, Krammer G, Rebuli R, Toth E. 2008. Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. Clinical Gastroenterology and Hepatology. 6(5):536-544. https://doi.org/10.1016/j.cgh.2007.12.023

MLA

Vancouver

Author

Hawkey, Christopher J ; Ell, Christian ; Simon, Bernd ; Albert, Joerg ; Keuchel, Martin ; Mcalindon, Mark ; Fortun, Paul ; Schumann, Stefan ; Bolten, Wolfgang ; Shonde, Anthony ; Hugot, Jean-Louis ; Yu, Vincent ; Arulmani, Udayasankar ; Krammer, Gerhard ; Rebuli, Rosemary ; Toth, Ervin. / Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole. I: Clinical Gastroenterology and Hepatology. 2008 ; Vol. 6, Nr. 5. s. 536-544.

RIS

TY - JOUR

T1 - Less small-bowel injury with lumiracoxib compared with naproxen plus omeprazole

AU - Hawkey, Christopher J

AU - Ell, Christian

AU - Simon, Bernd

AU - Albert, Joerg

AU - Keuchel, Martin

AU - Mcalindon, Mark

AU - Fortun, Paul

AU - Schumann, Stefan

AU - Bolten, Wolfgang

AU - Shonde, Anthony

AU - Hugot, Jean-Louis

AU - Yu, Vincent

AU - Arulmani, Udayasankar

AU - Krammer, Gerhard

AU - Rebuli, Rosemary

AU - Toth, Ervin

N1 - The information about affiliations in this record was updated in December 2015. The record was previously connected to the following departments: Emergency medicine/Medicine/Surgery (013240200)

PY - 2008

Y1 - 2008

N2 - Background & Aims: The selective cyclooxygenase-2 inhibitor lumiracoxib has been shown to reduce endoscopically detected ulcers and ulcer complications in the upper gastrointestinal tract compared with nonselective nonsteroidal anti-inflammatory drugs. We investigated whether lumiracoxib would reduce small-bowel injury compared with naproxen plus omeprazole. Methods: Healthy volunteers were randomized to receive lumiracoxib, 100 mg once daily, naproxen 500 mg twice daily plus omeprazole 20 mg once daily, or placebo in a 16-day double-blind, parallel-group study. Small-bowel mucosal injury and inflammation were assessed by video capsule endoscopy, the lactulose:L-rhamnose permeability assessment, and the fecal calprotectin test. Results: Of 152 randomized subjects, 139 completed the study with valid video capsule endoscopies (lumiracoxib, n = 47; naproxen plus omeprazole, n = 45; placebo, n = 47). Compared with placebo, an increased number of subjects on naproxen plus omeprazole had small-bowel mucosal breaks (77.8% vs 40.4%, P < .001), with increased permeability (P = .023) and increased fecal calprotectin (increase, 96.8 vs 14.5 mg/kg for placebo; P < .001). With lumiracoxib, 27.7% of subjects had small-bowel mucosal breaks (P = .196 vs placebo; P < .001 vs naproxen), there was no increase in permeability (P = .157 vs placebo; P = .364 vs naproxen), and no increase in fecal calprotectin (-5.7 mg/kg; P = .377 vs placebo; P < .001 vs naproxen). Conclusions: As assessed by 3 different measures, acute small-bowel injury on lumiracoxib treatment is less frequent than with naproxen plus omeprazole and similar to placebo.

AB - Background & Aims: The selective cyclooxygenase-2 inhibitor lumiracoxib has been shown to reduce endoscopically detected ulcers and ulcer complications in the upper gastrointestinal tract compared with nonselective nonsteroidal anti-inflammatory drugs. We investigated whether lumiracoxib would reduce small-bowel injury compared with naproxen plus omeprazole. Methods: Healthy volunteers were randomized to receive lumiracoxib, 100 mg once daily, naproxen 500 mg twice daily plus omeprazole 20 mg once daily, or placebo in a 16-day double-blind, parallel-group study. Small-bowel mucosal injury and inflammation were assessed by video capsule endoscopy, the lactulose:L-rhamnose permeability assessment, and the fecal calprotectin test. Results: Of 152 randomized subjects, 139 completed the study with valid video capsule endoscopies (lumiracoxib, n = 47; naproxen plus omeprazole, n = 45; placebo, n = 47). Compared with placebo, an increased number of subjects on naproxen plus omeprazole had small-bowel mucosal breaks (77.8% vs 40.4%, P < .001), with increased permeability (P = .023) and increased fecal calprotectin (increase, 96.8 vs 14.5 mg/kg for placebo; P < .001). With lumiracoxib, 27.7% of subjects had small-bowel mucosal breaks (P = .196 vs placebo; P < .001 vs naproxen), there was no increase in permeability (P = .157 vs placebo; P = .364 vs naproxen), and no increase in fecal calprotectin (-5.7 mg/kg; P = .377 vs placebo; P < .001 vs naproxen). Conclusions: As assessed by 3 different measures, acute small-bowel injury on lumiracoxib treatment is less frequent than with naproxen plus omeprazole and similar to placebo.

U2 - 10.1016/j.cgh.2007.12.023

DO - 10.1016/j.cgh.2007.12.023

M3 - Article

VL - 6

SP - 536

EP - 544

JO - Clinical Perspectives in Gastroenterology

JF - Clinical Perspectives in Gastroenterology

SN - 1542-7714

IS - 5

ER -